HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ODM-204

nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1

Also Known As:

4-(((1R)-3-Imidazol-1-yl-6,6-dimethylcyclohex-2-en-1-yl)-methylamino)-2-(trifluoromethyl)benzonitrile

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - ODM-204: 2

Experts

1.	Oksala, Riikka: 2 articles (01/2020 - 01/2019)
2.	Bono, Petri: 1 article (01/2020)
3.	Fizazi, Karim: 1 article (01/2020)
4.	Jones, Robert Hugh: 1 article (01/2020)
5.	Massard, Christophe: 1 article (01/2020)
6.	Mustonen, Mika V J: 1 article (01/2020)
7.	Nykänen, Pirjo: 1 article (01/2020)
8.	Peltola, Katriina J: 1 article (01/2020)
9.	Pohjanjousi, Pasi: 1 article (01/2020)
10.	Vjaters, Egils: 1 article (01/2020)

Related Diseases

1.

Prostatic Neoplasms (Prostate Cancer)

01/01/2020 - "This study looked at the safety of ODM-204, a novel dual inhibitor of CYP17A1 and the androgen receptor, in castration-resistant prostate cancer patients. "
01/01/2020 - "ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer."
01/01/2019 - "We report the discovery of a novel nonsteroidal dual-action compound, ODM-204, that holds promise for treating patients with castration-resistant prostate cancer (CRPC), an advanced form of prostate cancer characterised by high androgen receptor (AR) expression and persistent activation of the AR signaling axis by residual tissue androgens. "

Related Drugs and Biologics

1.	Androgen Receptors (Androgen Receptor)
2.	Androgens

Related Therapies and Procedures

1.	Castration